Strategic Partnerships Position ADM Diagnostics as a centralized imaging partner for pharma and academic collaborations, highlighting capabilities to provide centralized imaging acquisition and analysis, differentiating from competitors with a proprietary brain image analysis platform.

Early Diagnosis Advantage Leverage the focus on early and more accurate diagnosis of Alzheimer’s and other brain disorders to target pharma companies developing disease-modifying therapies, offering diagnostic support tools and biomarker-rich imaging analytics to stratify trial participants.

Niche Grant Cred Capitalize on NIH and grant-funded milestones to demonstrate credibility and de-risk partner engagements, using the recent $1.96M awards to validate capabilities for head impact research and disease differentiation in trials.

Clinical Outcomes Highlight the ability to differentiate dementia forms, predict cognitive decline rates, and detect drug effects on the brain to support patient stratification, trial endpoints, and pharmacovigilance across neuroscience programs.

Growth Readiness Target larger contract research organizations and diagnostic labs by underscoring scalable imaging analysis services, potential revenue channels from pharma collaborations, and a proven track record with grant-backed funding to accelerate business development conversations.